Investors Advised to Act Quickly in Class Action Against Park Ha Biological Technology Co., Ltd.

Investor Alert: Class Action Lawsuit Against Park Ha Biological Technology Co., Ltd.

The Pomerantz Law Firm has made public a warning for investors involved with Park Ha Biological Technology Co., Ltd. regarding a class action lawsuit currently in progress. If you have incurred financial losses as a result of your investments in Park Ha, it is crucial for you to be aware of the deadlines pertaining to this lawsuit. The impending deadline to request your designation as Lead Plaintiff is September 28, 2026.

The class action centers on allegations that Park Ha and its senior management may have engaged in securities fraud or other questionable business practices. Investors are encouraged to reach out to Danielle Peyton at the email address provided by Pomerantz or by calling for further details. Those interested in joining the class action should also provide their contact information and details of their investment transactions.

The complaint outlines a troubling narrative where Park Ha is suspected of falling victim to a pump-and-dump scheme. This involved misinformation spread across social media platforms, including individuals posing as financial experts, which contributed to the misleading perception of the company’s stock performance. From an initial public offering (IPO) price of $4.00, Park Ha's stock price astonishingly surged to an unprecedented high of $41.49 on July 7, 2025, despite lacking any significant corporate developments or authentic business prospects that would justify such an increase.

Subsequent investigations have indicated that social media promotions played a significant role in the manipulation of Park Ha's stock price, with impersonators misleading investors by making baseless claims online about the company's future and potential. This narrative is alarming for investors and indicates serious concerns regarding the integrity of the financial channels and the role of misleading information in stock price fluctuations.

Pomerantz LLP is recognized globally for its expertise in corporate, securities, and antitrust class litigation. With over 85 years of experience, the firm is committed to fighting for the rights of victims affected by corporate misconduct and securities fraud. Pomerantz has a noteworthy track record in recovering considerable financial awards for class members impacted by fraudulent activities in the market. Their commitment to justice and transparency in corporate dealings is well-established, and they continue to advocate diligently on behalf of investors.

Given the complexity of securities law and the potential ramifications for affected investors, it’s crucial that individuals who believe they have been wronged take action promptly. The filing of this class action lawsuit not only seeks restitution for losses but also aims to hold accountable those responsible for the alleged fraudulent activities that have unjustly impacted investors’ financial wellbeing.

It's vital for investors to remain informed and active during such proceedings. For additional information about the class action lawsuit against Park Ha Biological Technology Co., Ltd., or to inquire about your eligibility, contact Pomerantz Law Firm as soon as possible.

The firm’s dedication to protecting investor rights serves as a rallying call for those who have suffered due to the alleged misdeeds of Park Ha. Don’t miss the opportunity to participate in this important legal initiative that aims to restore integrity and justice in the growing sector of biotechnology.

For more information, visit Pomerantz Law Firm or contact them directly to understand your rights as an investor.